Folkman maintained close ties with EntreMed until his death. In the 2005 interview, he blamed the failure of the drug not on the company, which found the drug difficult and expensive to make, but on FDA reporting conventions. He said that the FDA measures success by tumor shrinkage, a standard appropriate only for chemotherapy agents, and that it needs to develop "language" for the kind of recovery that patients like Toner experienced.
Today, Endostatin is in development in China under the name Endostar, but it is unclear if or how it will be approved in the United States.
Toner is taking Avastin. He and his wife now have a second child.
"I don't know if my daughter is the first Avastin baby," he said. "But I can tell you that I'm looking forward to turning 40. I didn't plan on that when I was on chemo."